Overview

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Formulations
Market Cap: 135 Cr
Volatility: Low Risk
P/E Ratio: 2.6
Industry P/E: 42.6
PEG Ratio: 0.0
P/B Ratio: 4.4
52W High: 208.00
52W Low: 150.10

Sales CAGR

1Y: 219.36%
3Y: —
5Y: —
10Y: —

Profit CAGR

1Y: 218.29%
3Y: —
5Y: —
10Y: —

ROE

TTM: —
3Y: 55.48%
5Y: —
10Y: —

ROCE

TTM: —
3Y: 50.84%
5Y: —
10Y: —

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
QUESTLAB	108.35	175 Cr	13.09	1.95	0.00	12.05	12.15	10.18
CORALAB	452.70	157 Cr	11.56	0.74	0.00	8.14	10.97	6.01
PARNAXLAB	130.00	148 Cr	11.90	1.64	0.00	12.26	12.71	6.01
PHARMAID	35.80	120 Cr	-9.13	2.31	0.00	-31.40	-26.43	-15.53
MERCURYLAB	772.00	93 Cr	19.64	1.67	0.45	8.81	11.49	6.38
MAKERSL	149.25	84 Cr	72.80	1.19	0.00	-0.03	8.67	3.76

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Half Yearly Results (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Sep 2025
Sales	14
Expenses	11
Interest	0.26
Operating Profit	3.29
OPM %	23.40
Other Income	0.00
Depreciation	0.17
Profit Before Tax	2.87
Tax %	18.82
Net Profit	2.33
EPS in Rs	—

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Sales	2.90	5.01	16
Expenses	2.28	3.78	12
Operating Profit	0.62	1.22	3.72
OPM %	21.41	24.45	23.27
Other Income	0.17	0.19	0.05
Interest	0.19	0.24	0.35
Depreciation	0.31	0.26	0.24
Profit Before Tax	0.29	0.91	3.18
Tax %	2.37	10.14	17.85
Net Profit	0.28	0.82	2.61
EPS in Rs	—	—	—
Dividend Payout %	0.00	0.00	0.00

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Equity Capital	0.36	0.36	0.49
Reserves	-0.10	0.72	4.86
Borrowings	1.97	2.17	3.86
Other Liabilities	1.82	1.38	1.65
Total Liabilities	4.06	4.64	11
Fixed Assets	1.49	1.28	2.02
CWIP	0.00	0.10	0.00
Investments	0.00	0.00	0.00
Other Assets	2.57	3.25	8.85
Total Assets	4.06	4.64	11

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	0.68	0.23	-2.21
Cash from Investing Activity	-0.01	-0.16	-0.87
Cash from Financing Activity	-0.63	-0.04	2.98
Net Cash Flow	0.04	0.03	-0.10

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Sep 2025	Jan 2026	Feb 2026
Promoters	100.00%	100.00%	67.96%
FIIs	0.00%	0.00%	6.04%
DIIs	0.00%	0.00%	6.51%
Public	0.00%	0.00%	19.50%
Total Shareholders	10	10	407

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Projection

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Accretion Nutraveda Ltd

Accretion Nutraveda Ltd (N/A) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Accretion Nutraveda Ltd operates in the Pharmaceuticals sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.

Over the past 52 weeks, Accretion Nutraveda Ltd has traded between a low of ₹0.00 and a high of ₹208.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Accretion Nutraveda Ltd has a market capitalization of approximately 134.66. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Accretion Nutraveda Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 2.59 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 134.66 Cr, Accretion Nutraveda Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Accretion Nutraveda Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Accretion Nutraveda Ltd is 2.59. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Accretion Nutraveda Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison